Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Assistant, Research
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Terminated	3	194	Europe, Canada, US, RoW	Clazakizumab, Physiologic saline solution	CSL Behring, ICON Clinical Research	Antibody-mediated Rejection	04/24	04/24
MONARCH, NCT04442295: An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	Completed	1/2	62	US	STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses	Stoke Therapeutics, Inc	Dravet Syndrome	12/23	04/24
EAMP1, NCT04438512: A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD	No Longer Available	N/A		US	Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA, midomafetamine HCl, Psychotherapy	Lykos Therapeutics	Post Traumatic Stress Disorder